Kexing Biopharm's Licensed-In Product - Bevacizumab Receives Marketing Approval in Bolivia

Article source：Kexing BiopharmNov 17,2025View： 357

Recently, Kexing Biopharm Co., Ltd. (688136.SH) announced that its licensed-in product, a bevacizumab biosimilar, has officially received marketing approval from Bolivia's National Agency of Medicines and Health Technologies (AGEMED). This marks the fifth country to approve the product following Kexing Biopharm's collaboration with BioDlink on bevacizumab.

Bevacizumab is a commonly used drug in the field of oncology, approved worldwide for the treatment of various cancers. It stands as a blockbuster product in oncology therapeutics that cannot be overlooked.

According to data from the China Pharmaceutical Health Products Import & Export Association, China's pharmaceutical exports to emerging markets such as ASEAN, Latin America, and Africa showed steady growth in 2024, with Latin America recording an increase of 11.4%. The emerging pharmaceutical markets in Latin America have long been a key commercialization region for the company. This approval in Bolivia lays a solid foundation for further deepening penetration in the region.

Since the beginning of this year, multiple overseas products from the company have successively obtained marketing approvals in various countries. The bevacizumab biosimilar has secured registrations and approvals in five countries, including Pakistan and Indonesia, with registration efforts advancing rapidly in more than 20 additional countries. The company has established subsidiaries in the Latin American region and assembled localized operational teams. Moving forward, it will meticulously cultivate this market, further increasing its market share and contributing to enhanced drug accessibility for local populations.

About Kexing Biopharm

Kexing Biopharm (Stock Code: 688136.SH) is a multinational biopharmaceutical enterprise that engages in the R&D, manufacture and sales of innovative medicines of distinct modalities including recombinant proteins, antibodies, and targeted delivery therapies.

Through building cutting-edge technology platforms to advance the development of novel targeted therapies and drug delivery systems, Kexing strives to address unmet clinical needs in the areas of oncology, autoimmune and antiviral treatment, creating a significant and meaningful positive impact on patients' lives.

By adhering to the platform development model driven by the twin engines of “Innovation & Internationalization”, Kexing is committed to becoming a world leader in high-quality biopharmaceuticals, improving the health of patients worldwide.